Avalo Therapeutics, Inc.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
0.18 |
1.00 |
1.00 |
1.00 |
0.17 |
22.10 |
| Przychód Δ r/r |
0.00% |
446.45% |
0.00% |
0.00% |
-83.22% |
13070.36% |
| Przychód (min) |
0.16 |
1.00 |
1.00 |
1.00 |
0.17 |
22.10 |
| Przychód (max) |
0.20 |
1.00 |
1.00 |
1.00 |
0.17 |
22.10 |
| EBITDA (średnia) |
-0.18 |
-1.00 |
-1.00 |
-1.00 |
-0.17 |
-22.10 |
| EBIT (średnia) |
-0.18 |
-1.00 |
-1.00 |
-1.00 |
-0.17 |
-22.10 |
| EBIT % |
-100.00% |
-100.00% |
-100.00% |
-100.00% |
-100.00% |
-100.00% |
| Zysk netto (średni) |
-198.88 |
-53.56 |
-66.93 |
-71.89 |
-39.04 |
-39.74 |
| Zysk netto % |
-108676.17% |
-5356.18% |
-6693.17% |
-7188.60% |
-23264.59% |
-179.82% |
| EPS (średnia) |
-18.45 |
-4.97 |
-4.89 |
-4.57 |
-3.62 |
-3.69 |
| Liczba analityków (Przychody) |
4 |
1 |
7 |
5 |
1 |
2 |
| Liczba analityków (EPS) |
2 |
2 |
5 |
4 |
3 |
2 |
| symbol |
AVTX |
AVTX |
AVTX |
AVTX |
AVTX |
AVTX |